Qualitative or quantitative defects of plectin

Qualitative or quantitative defects of plectin encompass a group of rare genetic disorders caused by mutations in the PLEC gene, which encodes plectin, a large cytoskeletal linker protein critical for maintaining the structural integrity of cells in the skin, muscles, and other tissues. Plectin connects intermediate filaments to other cytoskeletal elements and to cell junctions such as hemidesmosomes in the skin and desmin networks in muscle. When plectin is absent, reduced, or dysfunctional, multiple organ systems can be affected. The most well-recognized condition associated with plectin defects is epidermolysis bullosa simplex with muscular dystrophy (EBS-MD), also known as EBS-Ogna or plectin-related epidermolysis bullosa. Patients typically present with skin fragility and blistering from birth or early infancy, which can range from mild to severe. Over time, progressive muscular dystrophy develops, often becoming apparent in childhood or adolescence, affecting skeletal muscles and sometimes cardiac muscle. Other features may include pyloric or urogenital atresia, nail dystrophy, dental abnormalities, and respiratory complications. Some patients may present predominantly with skin findings, while others develop significant neuromuscular involvement depending on the specific mutation and whether it leads to complete absence of plectin (quantitative defect) or production of a dysfunctional protein (qualitative defect). There is currently no cure for plectin-related disorders. Management is supportive and multidisciplinary, involving dermatological wound care to prevent and treat blistering, physical therapy and orthopedic management for muscular dystrophy, cardiac monitoring, nutritional support, and respiratory care as needed. Genetic counseling is recommended for affected families. Research into gene therapy and other molecular approaches is ongoing but remains in early stages.

Common questions about Qualitative or quantitative defects of plectin